+

WO1998035985B1 - Protein markers for lung cancer and use thereof - Google Patents

Protein markers for lung cancer and use thereof

Info

Publication number
WO1998035985B1
WO1998035985B1 PCT/IB1998/000361 IB9800361W WO9835985B1 WO 1998035985 B1 WO1998035985 B1 WO 1998035985B1 IB 9800361 W IB9800361 W IB 9800361W WO 9835985 B1 WO9835985 B1 WO 9835985B1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
animal
human
spot
lung cancer
Prior art date
Application number
PCT/IB1998/000361
Other languages
French (fr)
Other versions
WO1998035985A1 (en
Filing date
Publication date
Application filed filed Critical
Priority to DK98905576T priority Critical patent/DK0961780T3/en
Priority to DE69837529T priority patent/DE69837529T2/en
Priority to NZ337750A priority patent/NZ337750A/en
Priority to EP98905576A priority patent/EP0961780B1/en
Priority to AU61112/98A priority patent/AU6111298A/en
Priority to CA2280930A priority patent/CA2280930C/en
Priority to JP53551498A priority patent/JP4367866B2/en
Publication of WO1998035985A1 publication Critical patent/WO1998035985A1/en
Publication of WO1998035985B1 publication Critical patent/WO1998035985B1/en

Links

Abstract

Computerized analysis of 2-D gels, both carrier ampholyte (CA) and immobilized pH gradient (IPG) based, of the proteins in tissue from lung tumors, reveals proteins which are different types of tumors and in control tissues.

Claims

AMENDED CLAIMS
[received by the International Bureau on 25 September 1998 (25.09.98); new claims 19-24 added, remaining claims unchanged (1 page)]
18. A method of treating a tumor in an animal or human in need thereof
comprising: a) exposing immunocompetent cells from the animal or human to at least
one protein selected from the group consisting of Spot 14, 15, 16, 17, 21 , 22, 27,
29, 31 , 33, 40, 42, 43, 47, 50, 53, 57, 58, 59, 61 , 62, 66, 67, 68, 73, 74, 79, 80,
81 , 83, 84, 86, 90, 92, 94, 95, 96, 97, 98, 100, 101 , 102, 105, 106, 107, and 109;
and b) injecting said immunocompetent cells into the animal or human to treat
a tumor.
19. A method for diagnosing lung cancer in an animal or human,
comprising detecting at least one protein which is overexpressed in lung tumors
in a sample from the animal or human, and correlating the detection of the
protein with the presence of lung tumor.
20. The method of claim 19, wherein the sample is serum.
21. The method of claim 19, wherein the at least one protein is spot 107
or spot 109.
22. A method for diagnosing lung cancer in an animal or human,
comprising detecting the overexpression of at least one protein which is
overexpressed in lung tumors in a sample from the animal or human, and
correlating the overexpression of the protein with the presence of lung tumor.
23. The method of claim 22, wherein the sample is serum.
24. The method of claim 22, wherein the at least one protein is spot 107
or spot 109.
PCT/IB1998/000361 1997-02-12 1998-02-12 Protein markers for lung cancer and use thereof WO1998035985A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DK98905576T DK0961780T3 (en) 1997-02-12 1998-02-12 Protein markers for lung cancer and its use
DE69837529T DE69837529T2 (en) 1997-02-12 1998-02-12 PROTEIN MARKERS FOR LUNG CANCER AND ITS USE
NZ337750A NZ337750A (en) 1997-02-12 1998-02-12 Protein markers for lung cancer and use thereof
EP98905576A EP0961780B1 (en) 1997-02-12 1998-02-12 Protein markers for lung cancer and use thereof
AU61112/98A AU6111298A (en) 1997-02-12 1998-02-12 Protein markers for lung cancer and use thereof
CA2280930A CA2280930C (en) 1997-02-12 1998-02-12 Protein markers for lung cancer and use thereof
JP53551498A JP4367866B2 (en) 1997-02-12 1998-02-12 Protein markers for lung cancer and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3881997P 1997-02-12 1997-02-12
US60/038,819 1997-02-12

Publications (2)

Publication Number Publication Date
WO1998035985A1 WO1998035985A1 (en) 1998-08-20
WO1998035985B1 true WO1998035985B1 (en) 1998-11-12

Family

ID=21902087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1998/000361 WO1998035985A1 (en) 1997-02-12 1998-02-12 Protein markers for lung cancer and use thereof

Country Status (11)

Country Link
US (2) US20020192228A1 (en)
EP (1) EP0961780B1 (en)
JP (1) JP4367866B2 (en)
AT (1) ATE359515T1 (en)
AU (1) AU6111298A (en)
CA (1) CA2280930C (en)
DE (1) DE69837529T2 (en)
DK (1) DK0961780T3 (en)
ES (1) ES2284200T3 (en)
NZ (1) NZ337750A (en)
WO (1) WO1998035985A1 (en)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737514B1 (en) 1998-12-22 2004-05-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6660838B1 (en) 1998-03-18 2003-12-09 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6696247B2 (en) 1998-03-18 2004-02-24 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6312695B1 (en) 1998-03-18 2001-11-06 Corixa Corporation Compounds and methods for therapy of lung cancer
US6426072B1 (en) 2000-08-02 2002-07-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6821518B1 (en) 1998-03-18 2004-11-23 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US7049063B2 (en) 1998-03-18 2006-05-23 Corixa Corporation Methods for diagnosis of lung cancer
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6960570B2 (en) 1998-03-18 2005-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US6706262B1 (en) 1998-03-18 2004-03-16 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6482597B1 (en) 1999-12-17 2002-11-19 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6531315B1 (en) 1998-03-18 2003-03-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6518256B1 (en) 1998-03-18 2003-02-11 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
AU773265B2 (en) * 1998-11-05 2004-05-20 Regents Of The University Of Michigan, The S100 proteins and autoantibodies as serum markers for cancer
AU2004201392B2 (en) * 1998-11-05 2007-06-14 The Regents Of The University Of Michigan S100 proteins and autoantibodies as serum markers for cancer
EP1169347B1 (en) * 1999-04-02 2008-07-02 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
JP3524537B2 (en) 1999-11-22 2004-05-10 ディアデクサス インコーポレーテッド Novel methods for diagnosing, monitoring, staging, imaging and treating cancer
WO2002057741A2 (en) 2000-11-02 2002-07-25 Molecular Discoveries, L.L.C. Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
EP1373896A2 (en) * 2001-03-12 2004-01-02 MonoGen, Inc. Cell-based detection and differentiation of disease states
EP1519749B1 (en) * 2002-07-05 2009-04-08 Universite Laval Chemotactic factor inhibitor for inhibiting inflammatory reactions
AU2002951153A0 (en) * 2002-09-02 2002-09-19 Proteome Systems Intellectual Property Pty Ltd An electrophoresis gel having improved swelling properties
CA2565872C (en) * 2004-05-11 2016-06-21 Abgenomics Corporation T-cell death-inducing epitopes
CA2573596A1 (en) * 2004-07-13 2006-01-19 Universite Laval S100 protein inhibitors for treating leukemia
TR200700896T1 (en) * 2004-07-23 2007-04-24 Aspenbio, Inc. Methods and devices for the diagnosis of appendicitis
US7659087B2 (en) * 2004-07-23 2010-02-09 Aspenbio Pharma, Inc. Methods and devices for diagnosis of appendicitis
AR055057A1 (en) 2005-05-18 2007-08-01 Array Biopharma Inc HETEROCICLIC INHIBITORS OF MEK, CRYSTAL FORMS OF THE SAME, PROCESSES FOR THEIR PREPARATION AND METHODS OF USE OF THE SAME IN PHARMACEUTICAL COMPOSITIONS AND MEDICINES FOR THE TREATMENT OF A HYPERPROLIFERATIVE DISORDER OR OF AN INFLAMMATORY CONDITION.
KR100732298B1 (en) * 2005-11-24 2007-06-25 이화여자대학교 산학협력단 Cancer metastasis diagnostic composition using ubiquitin C-terminal hydrolyzate-L1
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
CL2007002225A1 (en) 2006-08-03 2008-04-18 Astrazeneca Ab SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
DK2057156T3 (en) 2006-08-23 2017-05-08 Kudos Pharm Ltd 2-METHYLMORPHOLINPYRIDO, PYRAZO AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS
EP2138497A4 (en) 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co Novel adenine compound
TW200902018A (en) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
CN104297490A (en) * 2007-09-11 2015-01-21 癌症预防和治疗有限公司 Identification of proteins in human serum indicative of pathologies of human lung tissues
MX2010003927A (en) 2007-10-11 2010-04-30 Astrazeneca Ab Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors.
WO2009085983A1 (en) 2007-12-19 2009-07-09 Genentech, Inc. 5-anilinoimidazopyridines and methods of use
KR20100099185A (en) 2007-12-21 2010-09-10 제넨테크, 인크. Azaindolizines and methods of use
JP5778577B2 (en) 2008-09-19 2015-09-16 メディミューン，エルエルシー Antibodies against DLL4 and uses thereof
TW201028410A (en) 2008-12-22 2010-08-01 Astrazeneca Ab Chemical compounds 610
CA2748158A1 (en) 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
US8426402B2 (en) 2009-02-05 2013-04-23 Immunogen, Inc. Benzodiazepine derivatives
EP2406401A4 (en) 2009-03-12 2013-01-09 Cancer Prevention & Cure Ltd Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy
EP2406258B1 (en) 2009-03-13 2014-12-03 Cellzome Limited PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
CA2758614A1 (en) 2009-04-14 2010-10-21 Cellzome Limited Fluoro substituted pyrimidine compounds as jak3 inhibitors
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
US20120172385A1 (en) 2009-09-11 2012-07-05 Richard John Harrison Ortho substituted pyrimidine compounds as jak inhibitors
US9242987B2 (en) 2009-10-20 2016-01-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
EP2507237A1 (en) 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
EP2521920A4 (en) * 2010-01-08 2013-06-05 Univ California PROTEIN MARKERS FOR DETECTION OF LUNG CANCER AND METHODS OF USE THEREOF
BR112012020102A2 (en) 2010-02-10 2016-11-29 Immunogen Inc cd20 antibodies and uses thereof.
ES2535116T3 (en) 2010-03-04 2015-05-05 Cellzome Limited Urea derivatives with morpholino as mtor inhibitors
EA201291038A1 (en) 2010-04-30 2013-05-30 Целльзом Лимитид PYRAZOL COMPOUNDS AS JAK INHIBITORS
SA111320519B1 (en) 2010-06-11 2014-07-02 Astrazeneca Ab Pyrimidinyl compounds for use as ATR inhibitors
EP2588105A1 (en) 2010-07-01 2013-05-08 Cellzome Limited Triazolopyridines as tyk2 inhibitors
JP2013534233A (en) 2010-08-20 2013-09-02 セルゾーム リミティッド Heterocyclylpyrazolopyrimidine analogs as selective JAK inhibitors
AU2011328237A1 (en) 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
US9353127B2 (en) 2011-02-15 2016-05-31 Immunogen, Inc. Methods of preparation of conjugates
DK2675793T3 (en) 2011-02-17 2018-11-12 Cancer Therapeutics Crc Pty Ltd FAK INHIBITORS
CN103534240B (en) 2011-02-17 2015-12-09 癌症疗法Crc私人有限公司 Selectivity Fak inhibitor
EP2694511A1 (en) 2011-04-04 2014-02-12 Cellzome Limited Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
BR112014000360A2 (en) 2011-07-28 2017-02-14 Cellzome Ltd heterocyclyl pyrimidine analogs as jak inhibitors
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
JP2014531449A (en) 2011-09-20 2014-11-27 セルゾーム リミティッド Pyrazolo [4,3-c] pyridine derivatives as kinase inhibitors
ES2609606T3 (en) 2011-09-21 2017-04-21 Cellzome Limited Urea and carbamate derivatives of 2-morpholino-1,3,5-triazine as mTOR inhibitors for the treatment of immunological or proliferative diseases
EP2763985B1 (en) 2011-10-07 2016-06-22 Cellzome Limited {(4-(4-morpholino-dihydrothieno[3,4-d]pyrimidin-2-yl)aryl}urea or carbamate derivatives as mtor inhibitors
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
AU2012357038B2 (en) 2011-12-23 2016-05-12 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9732161B2 (en) 2012-06-26 2017-08-15 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
WO2014026243A1 (en) 2012-08-17 2014-02-20 Cancer Therapeutics Crc Pty Limited Vegfr3 inhibitors
EP2887965A1 (en) 2012-08-22 2015-07-01 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
BR112015004022B1 (en) 2012-08-31 2023-04-25 Sutro Biopharma, Inc MODIFIED AMINO ACIDS COMPRISING AN AZID GROUP
WO2014041349A1 (en) 2012-09-12 2014-03-20 Cancer Therapeutics Crc Pty Ltd Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
EP2961435B1 (en) 2013-02-28 2019-05-01 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US9999680B2 (en) 2013-02-28 2018-06-19 Immunogen, Inc. Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents
AR095443A1 (en) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii HEREROCICLES CONDENSED WITH ACTION ON ATR
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
EP3336103B1 (en) 2013-07-10 2021-03-17 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
AU2017212739B2 (en) 2016-01-27 2024-03-21 Sutro Biopharma, Inc. Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates
CN107459519A (en) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 Annelated pyrimidines piperidines ring derivatives and its preparation method and application
US10870694B2 (en) 2016-09-02 2020-12-22 Dana Farber Cancer Institute, Inc. Composition and methods of treating B cell disorders
AU2017372722B2 (en) 2016-12-05 2021-09-09 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
CA3058481A1 (en) 2017-04-04 2018-10-11 Lung Cancer Proteomics, Llc Plasma based protein profiling for early stage lung cancer prognosis
WO2019023316A1 (en) 2017-07-26 2019-01-31 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
AU2018333945B2 (en) 2017-09-18 2025-06-12 Sutro Biopharma, Inc. Anti- folate receptor alpha antibody conjugates and their uses
NL2019801B1 (en) 2017-10-25 2019-05-02 Univ Leiden Delivery vectors
TW202003475A (en) 2018-06-04 2020-01-16 美商亞博創新醫藥有限公司 Pyrimidine compounds containing acidic groups
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
WO2020060944A1 (en) 2018-09-17 2020-03-26 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
EP3962951A1 (en) 2019-05-03 2022-03-09 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
US20220298143A1 (en) 2019-08-31 2022-09-22 Etern Biopharma (Shanghai) Co., Ltd. Pyrazole Derivatives for FGFR Inhibitor and Preparation Method Thereof
WO2021178597A1 (en) 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
WO2024006542A1 (en) 2022-06-30 2024-01-04 Sutro Biopharma, Inc. Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates
US20250122306A1 (en) 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019497A (en) * 1984-11-09 1991-05-28 Lennart Olsson Human squamous lung carcinoma cell specific antigens and antibodies
DK276185D0 (en) * 1984-11-09 1985-06-19 Novo Industri As MONOCLONAL ANTIBODIES, METHOD OF PREPARING THESE AND THEIR DIAGNOSTIC USES
US5171665A (en) * 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
CH685959A5 (en) * 1992-08-24 1995-11-15 Biomedicals Ag Diagnostic test kit for the determination of proteins.
EP0695760A1 (en) * 1994-08-05 1996-02-07 F. Hoffmann-La Roche Ag Novel tumor marker for lung cancer
US6107103A (en) * 1996-10-15 2000-08-22 Procyon Bropharma Inc. Assay for PSP94 protein

Similar Documents

Publication Publication Date Title
WO1998035985B1 (en) Protein markers for lung cancer and use thereof
DE69837529D1 (en) PROTEIN MARKERS FOR LUNG CANCER AND ITS USE
TAYLOR et al. Immunofluorescent localization of vitamin D-dependent calcium-binding protein
Ralston et al. The product of the protooncogene c-src is modified during the cellular response to platelet-derived growth factor.
Fitzgerald et al. Inhibition of intercellular communication by tumor-promoting phorbol esters
DE69519796D1 (en) PTPalpha determination in tumor diagnosis and prognosis
EA200501772A1 (en) METHODS OF MEASURING THE EXPRESSION OF GENES FROM FIXED AND PARULIN FABRIC SAMPLE
AU2001253079A1 (en) Methods, compositions and kits for the detection and monitoring of breast cancer
EP0762885A4 (en) GLOBAL MITOGENIC FACTORS, PREPARATION AND USE
Evans et al. Gene-specific DNA repair in xeroderma pigmentosum complementation groups A, C, D, and F. Relation to cellular survival and clinical features.
SE9500023D0 (en) Method of detecting cancer
NZ332641A (en) method of detecting a lysosomal storage disorder by assaying the level of an enzyme, protein or peptide associated with the disease
Brock Morphological and biochemical criteria for the separation of Cardium glaucum (Bruguière) from Cardium edule (L.)
EP0042482B1 (en) Process for detecting the presence of malignant and pre-malignant cells in humans
BR9609026A (en) Process composition for the treatment of cancer and detection for the production of cytokine by tumors to determine the efficacy of an autologous and diagnostic kit for detection for efficacy of autologous cellular compounds
DE60044350D1 (en) PROSTATE SPECIFIC GEN PCGEM1 AND METHODS OF USE FOR THE RECOGNITION, TREATMENT AND PREVENTION OF PROSTATE CANCER
CA2221495A1 (en) Methods and uses for apoptin
ATE365326T1 (en) METHOD FOR ANALYZING THE AMOUNT OF INTRA-ABDOMINAL FAT TISSUE
John et al. The detection and determination of L-tyrosine O-sulphate in rabbit and other mammalian urine
Presta et al. Human placental tissue stimulates bovine capillary endothelial cell growth, migration and protease production
CA2264963A1 (en) Protein markers for esophageal cancer
BR9611255A (en) nucleic acid, processes for determining a patient's susceptibility to cancer, for diagnosing cancer in a patient, for predicting the relative prospects for the particular appearance of cancer in a patient, for treating cancer and for determining the loss of heterozygosity in a tissue sample , system to detect the presence or absence of, or mutation, in the region of human chromosome 10, polypeptide, molecule and use of nucleic acid and a molecule.
DE69734199D1 (en) HUMAN NETRIN-1
Tofilon et al. BCNU-induced sister chromatid exchanges are increased by X irradiation
Mezele et al. Cation selectivity of membrane proteins
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载